[go: up one dir, main page]

DK3626270T3 - Behandling af kardiovaskulære sygdomme - Google Patents

Behandling af kardiovaskulære sygdomme Download PDF

Info

Publication number
DK3626270T3
DK3626270T3 DK19202854.6T DK19202854T DK3626270T3 DK 3626270 T3 DK3626270 T3 DK 3626270T3 DK 19202854 T DK19202854 T DK 19202854T DK 3626270 T3 DK3626270 T3 DK 3626270T3
Authority
DK
Denmark
Prior art keywords
treatment
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
DK19202854.6T
Other languages
English (en)
Inventor
Victor Chengwei Shi
Martin Lefkowitz
Adel Remond Rizkala
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3626270(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3626270T3 publication Critical patent/DK3626270T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DK19202854.6T 2013-08-26 2014-08-26 Behandling af kardiovaskulære sygdomme DK3626270T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2013/056680 WO2015030711A1 (en) 2013-08-26 2013-08-26 New use
US201461972933P 2014-03-31 2014-03-31
EP14761702.1A EP3038654B1 (en) 2013-08-26 2014-08-26 New use

Publications (1)

Publication Number Publication Date
DK3626270T3 true DK3626270T3 (da) 2024-01-15

Family

ID=51494327

Family Applications (3)

Application Number Title Priority Date Filing Date
DK23202190.7T DK4321157T3 (da) 2013-08-26 2014-08-26 Ny anvendelse af en kombination af en angiotensinreceptorblokker (arb) med en neutral endopeptidasehæmmer (nepi)
DK14761702.1T DK3038654T3 (da) 2013-08-26 2014-08-26 Ny anvendelse
DK19202854.6T DK3626270T3 (da) 2013-08-26 2014-08-26 Behandling af kardiovaskulære sygdomme

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK23202190.7T DK4321157T3 (da) 2013-08-26 2014-08-26 Ny anvendelse af en kombination af en angiotensinreceptorblokker (arb) med en neutral endopeptidasehæmmer (nepi)
DK14761702.1T DK3038654T3 (da) 2013-08-26 2014-08-26 Ny anvendelse

Country Status (16)

Country Link
US (2) US20160213646A1 (da)
EP (4) EP4321157B1 (da)
JP (1) JP6097888B2 (da)
CY (1) CY1122531T1 (da)
DK (3) DK4321157T3 (da)
ES (3) ES3001196T3 (da)
FI (2) FI3626270T3 (da)
HR (3) HRP20241763T1 (da)
HU (3) HUE047186T2 (da)
LT (3) LT3038654T (da)
PL (3) PL4321157T3 (da)
PT (3) PT3626270T (da)
RS (3) RS59816B1 (da)
SI (3) SI3038654T1 (da)
SM (1) SMT202500001T1 (da)
WO (1) WO2015028941A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59816B1 (sr) 2013-08-26 2020-02-28 Novartis Ag Nova primena
WO2016125123A1 (en) * 2015-02-06 2016-08-11 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
JP2018516267A (ja) * 2015-05-29 2018-06-21 ノバルティス アーゲー 代謝性疾患を治療するためのサクビトリルおよびバルサルタン
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
CN107510653A (zh) * 2016-06-17 2017-12-26 常州爱诺新睿医药技术有限公司 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN106491600A (zh) * 2015-09-06 2017-03-15 常州方楠医药技术有限公司 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
WO2017134597A1 (en) 2016-02-03 2017-08-10 Novartis Ag Galenic formulations of organic compounds
CN106176681A (zh) * 2016-08-25 2016-12-07 泰力特医药（湖北）有限公司 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN115487175B (zh) * 2019-09-20 2024-05-14 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59107440D1 (de) 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
ES2200310T3 (es) * 1997-01-10 2004-03-01 MERCK & CO., INC. Uso de antagonistas de la angiotensina ii losartan y exp-3174 en el tratamiento de la insuficiencia cardiaca sintomatica.
KR20100057704A (ko) * 2002-01-17 2010-05-31 노파르티스 아게 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
US20070054947A1 (en) * 2003-05-16 2007-03-08 Cohn Jay N Pharmaceutical composition comprising valsartan
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
MX2010004930A (es) 2007-11-06 2010-05-27 Novartis Ag Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep).
US20100143351A1 (en) 2008-11-22 2010-06-10 Genentech, Inc. Anti-Angiogenesis Therapy for the Treatment of Breast Cancer
CN103079554A (zh) 2010-08-24 2013-05-01 诺华有限公司 在接受抗凝血剂疗法的哺乳动物中治疗高血压和/或预防或治疗心力衰竭
CA2882771C (en) 2012-08-24 2021-02-23 Novartis Ag Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
WO2015030711A1 (en) * 2013-08-26 2015-03-05 Novartis Ag New use
RS59816B1 (sr) 2013-08-26 2020-02-28 Novartis Ag Nova primena

Also Published As

Publication number Publication date
HRP20240034T1 (hr) 2024-03-29
EP4512397A2 (en) 2025-02-26
SI3038654T1 (sl) 2020-02-28
PL3038654T3 (pl) 2020-05-18
PT3626270T (pt) 2024-01-11
RS59816B1 (sr) 2020-02-28
HRP20200060T1 (hr) 2020-04-03
EP4512397A3 (en) 2025-05-14
PT4321157T (pt) 2025-01-08
EP3626270B1 (en) 2023-10-11
FI4321157T3 (fi) 2025-01-20
LT3038654T (lt) 2020-01-27
JP2016528303A (ja) 2016-09-15
WO2015028941A1 (en) 2015-03-05
PT3038654T (pt) 2020-02-04
HUE047186T2 (hu) 2020-04-28
US20210077461A1 (en) 2021-03-18
EP4321157A2 (en) 2024-02-14
EP4321157A3 (en) 2024-05-15
EP4321157B1 (en) 2024-10-23
ES2767084T3 (es) 2020-06-16
PL3626270T3 (pl) 2024-04-08
ES3001196T3 (es) 2025-03-04
HUE064634T2 (hu) 2024-04-28
DK4321157T3 (da) 2024-12-16
CY1122531T1 (el) 2021-01-27
LT3626270T (lt) 2024-01-25
ES2968541T3 (es) 2024-05-10
SMT202500001T1 (it) 2025-03-12
EP3626270A1 (en) 2020-03-25
DK3038654T3 (da) 2020-02-03
FI3626270T3 (fi) 2024-01-11
HRP20241763T1 (hr) 2025-03-14
EP3038654B1 (en) 2019-10-30
SI4321157T1 (sl) 2025-03-31
PL4321157T3 (pl) 2025-03-03
SI3626270T1 (sl) 2024-03-29
RS66371B1 (sr) 2025-02-28
EP3038654A1 (en) 2016-07-06
JP6097888B2 (ja) 2017-03-15
LT4321157T (lt) 2025-01-10
RS65037B1 (sr) 2024-02-29
HUE069419T2 (hu) 2025-03-28
US20160213646A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
DK2968208T3 (da) Behandling af kataplexi
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3021838T3 (da) Behandling af fedme
DK3851537T5 (da) Behandling af hyperbilirubinæmi
LT2885010T (lt) Tautopatijos gydymo būdai
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
DK2846809T3 (da) Behandling af myelosuppression
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3087183T3 (da) Modulation af angiopoietin-3-lignende ekspression
DK2961388T3 (da) Kombinationer af lægemidler
LT3007726T (lt) Tautopatijos gydymo būdai
PT2953948T (pt) Antagonistas de integrina fluorada
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK2965026T3 (da) Generering af slushice
DK3511004T3 (da) Kombineret præparat til behandling af cancer
DK3063264T3 (da) Tørring af mikroorganismer
EP2945942A4 (en) Voriconazole IMMUNOASSAY
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
EP2988738A4 (en) THERAPEUTIC INDICATIONS OF KINASE INHIBITORS
DK3598971T3 (da) Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin
DK3024816T3 (da) Ppar-sparende forbindelser til behandling af metaboliske sygdomme
DK2968606T3 (da) Behandling af autoimmune sygdomme
IL239971A0 (en) Isometheptene isomer
DK3369435T3 (da) Sammensætning til behandling af inflammatorisk ledsygdom